CTMX insider trading
NasdaqGS HealthcareCytomX Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Company website: www.cytomx.com
CTMX insider activity at a glance
FilingIQ has scored 392 insider transactions for CTMX since May 7, 2015. The most recent filing in our index is dated Mar 17, 2026.
Across the full history, 8 open-market purchases
and 163 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CTMX insider trades is 52.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CTMX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading CTMX
Frequently asked
- How many insider trades does FilingIQ track for CTMX?
- FilingIQ tracks 392 Form 4 insider transactions for CTMX (CytomX Therapeutics, Inc.), covering filings from May 7, 2015 onwards. 4 of those were filed in the last 90 days.
- Are CTMX insiders net buyers or net sellers?
- Across the full Form 4 history for CTMX, 8 transactions (2%) were open-market purchases and 163 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CTMX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CTMX in?
- CytomX Therapeutics, Inc. (CTMX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $954.77M.
Methodology & sources
Every CTMX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.